Molecular Diagnostics for Gonorrhoea: Implications for Antimicrobial Resistance and the Threat of Untreatable Gonorrhoea

1. DaviesSC, FowlerT, WatsonJ, LivermoreDM, WalkerD (2013) Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance. Lancet 381: 1606–1609.

2. World Health Organization (2012) Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: World Health Organization.

3. IsonCA, TownK, ObiC, ChisholmS, HughesG, et al. (2013) Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis 13: 762–768.

4. OhnishiM, GolparianD, ShimutaK, SaikaT, HoshinaS, et al. (2011) Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55: 3538–3545.

5. TapsallJW, NdowaF, LewisDA, UnemoM (2009) Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 7: 821–834.

6. Zappa F (1979) Why does it hurt when I pee? Joe's Garage: Zappa Records.

7. UnemoM, NicholasRA (2012) Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 7: 1401–1422.

8. AllenVG, FarrellDJ, RebbapragadaA, TanJ, TijetN, et al. (2011) Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 55: 703–712.

9. LewisDA, SriruttanC, MullerEE, GolparianD, GumedeL, et al. (2013) Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 68: 1267–1270.

10. LawnSD, BrooksSV, KranzerK, NicolMP, WhitelawA, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8: e1001067.

11. DiekemaDJ, PfallerMA (2013) Rapid Detection of Antibiotic Resistant Organism Carriage for Infection Prevention. Clin Infect Dis 56: 1614–1620.

12. PaiNP, VadnaisC, DenkingerC, EngelN, PaiM (2012) Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 9: e1001306.

13. MenziesNA, CohenT, LinHH, MurrayM, SalomonJA (2012) Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347.

14. KatzAR, EfflerPV, OhyeRG, BrouilletB, LeeMV, et al. (2004) False-positive gonorrhea test results with a nucleic acid amplification test: the impact of low prevalence on positive predictive value. Clin Infect Dis 38: 814–819.

15. KlausnerJD (2004) The NAAT is out of the bag. Clin Infect Dis 38: 820–821.

16. HerrmannB, TornerA, LowN, KlintM, NilssonA, et al. (2008) A new genetic variant of Chlamydia trachomatis in Sweden: National study of impact on detection rates. Emerg Infect Dis 14: 1462–1465.

17. ZenilmanJM, MillerWC, GaydosC, RogersSM, TurnerCF (2003) LCR testing for gonorrhoea and chlamydia in population surveys and other screenings of low prevalence populations: coping with decreased positive predictive value. Sex Transm Infect 79: 94–97.

18. World Health Organization (2003) Guidelines for the Management of Sexually Transmitted Infections; Revised version 2003. Geneva: World Health Organization.

19. PittsMK, SmithAMA, MischewskiA, FairleyC (2005) Men, bodily change and urethritis: a qualitative study. Sex Health 2: 25–28.

20. BignellC, UnemoM (2013) 2012 European Guideline on the diagnosis and treatment of gonorrhoea. Int J STD AIDS 24: 85–92.

21. ClarkJL, LescanoAG, KondaKA, LeonSR, JonesFR, et al. (2009) Syndromic management and STI control in urban Peru. PLoS One 4: e7201.

22. WhileyDM, TapsallJW, SlootsTP (2006) Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn 8: 3–15.

23. DickerLW, MosureDJ, SteeceR, StoneKM (2007) Laboratory tests used in US public health laboratories for sexually transmitted diseases, 2004. Sex Transm Dis 34: 41–46.

24. IsonCA (2012) Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment. Curr Opin Infect Dis 25: 73–78.

25. SadiqST, DaveJ, ButcherPD (2010) Point-of-care antibiotic susceptibility testing for gonorrhoea: improving therapeutic options and sparing the use of cephalosporins. Sex Transm Infect 86: 445–446.

26. OhnishiM, SaikaT, HoshinaS, IwasakuK, NakayamaS, et al. (2011) Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17: 148–149.

27. YoungH, AndersonJ, MoyesA, McMillanA (1997) Non-cultural detection of rectal and pharyngeal gonorrhoea by the Gen-Probe PACE 2 assay. Genitourin Med 73: 59–62.

28. PriceIH, Menon-JohanssonA, DanielsD (2006) National Audit Group of the British Association for Sexual Health and HIV (2006) A national audit of gonorrhoea management. Int J STD AIDS 17: 133–134.

29. GoldenMR, HughesJP, ClesLE, CrouseK, GudgelK, et al. (2004) Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis 39: 1387–1390.

30. FuruyaR, OnoyeY, KanayamaA, SaikaT, IyodaT, et al. (2007) Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. J Infect Chemother 13: 302–304.

31. Centers for Disease Control and Prevention (2012) Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections MMWR. 61: 590–593.

32. BirkenmeyerL, ArmstrongAS (1992) Preliminary evaluation of the ligase chain reaction for specific detection of Neisseria gonorrhoeae. J Clin Microbiol 30: 3089–3094.

33. GoireN, FreemanK, TapsallJW, LambertSB, NissenMD, et al. (2011) Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol 49: 513–518.

34. LiZ, YokoiS, KawamuraY, MaedaS, EzakiT, et al. (2002) Rapid detection of quinolone resistance-associated gyrA mutations in Neisseria gonorrhoeae with a LightCycler. J Infect Chemother 8: 145–150.

35. MagooaMP, MullerEE, GumedeL, LewisDA (2013) Determination of Neisseria gonorrhoeae susceptibility to ciprofloxacin in clinical specimens from men using a real-time PCR assay. Int J Antimicrob Agents 42: 63–67.

36. BalashovS, MordechaiE, AdelsonME, GygaxSE (2013) Multiplex bead suspension array for screening Neisseria gonorrhoeae antibiotic resistance genetic determinants in noncultured clinical samples. J Mol Diagn 15: 116–129.

37. GoireN, OhnishiM, LimniosAE, LahraMM, LambertSB, et al. (2012) Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain. J Antimicrob Chemother 67: 902–905.

38. SmithR, CoastJ (2013) The true cost of antimicrobial resistance. BMJ 346: f1493.